

Paris Descartes. Dr. Menasche recently supervised a Phase I cardiomyocyte stem cell clinical trial in Paris, which received promising results and provides evidence of a proof of concept for work similar to IPS HEART.

IPS HEART recently presented results at the 82nd Annual Scientific Meeting of the Japanese Circulation Society showing ejection fraction (EF) improvement after 90 days in a mouse model of heart attack treated with human derived IPS H cardiomyocytes. These results are an improvement over previous cardiac stem cell trials, which showed at best 3% and lacked evidence of heart regeneration. The results further substantiate IPS HEART's approach.

With \$12 million in research funding thus far, IPS HEART is the first company to focus exclusively on the IPS cardiac stem cell. The company is currently raising venture capital to expand into global clinical trials.

Source:

1. <https://www.businesswire.com/news/home/20180619005262/en/IPS-HEART-Resident-Johnson-Johnson-Innova>

Featured Vendors



This website uses cookies to improve your experience. [Learn more](#) ACCEPT